144 related articles for article (PubMed ID: 34389273)
1. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Morcos PN; Moss J; Veasy J; Hiemeyer F; Childs BH; Garmann D
Clin Pharmacol Ther; 2024 May; 115(5):1092-1104. PubMed ID: 38226495
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
Sancho JM; Abrisqueta P; Kumar A; Cordoba R; Tani M; Langmuir P; Rappold E; Liu T; Lopez-Guillermo A
Leuk Lymphoma; 2024 Apr; ():1-11. PubMed ID: 38598516
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.
Harrison D; Gill J; Roth M; Hingorani P; Zhang W; Teicher B; Earley E; Erickson S; Gatto G; Kurmasheva R; Houghton P; Smith M; Anders Kolb E; Gorlick R
Pediatr Blood Cancer; 2023 Jan; 70(1):e30017. PubMed ID: 36250964
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
Morschhauser F; Ghosh N; Lossos IS; Palomba ML; Mehta A; Casasnovas O; Stevens D; Katakam S; Knapp A; Nielsen T; McCord R; Salles G
Blood Cancer J; 2021 Aug; 11(8):147. PubMed ID: 34417444
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view.
Thielen FW; Kersten MJ; Kuizenga P; Hoogendoorn M; Posthuma EF; Stevens WB; A Uyl-de Groot C; Blommestein HM
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1411-1422. PubMed ID: 34428992
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study comparing consolidation with a single dose of
López-Guillermo A; Canales MÁ; Dlouhy I; Mercadal S; Briones J; Martín García-Sancho A; Sancho JM; Moraleda JM; Terol MJ; Salar A; Palomera L; Gardella S; Jarque I; Ferrer S; Bargay J; López A; Panizo C; Muntañola A; Montalbán C; Conde E; Hernández MT; Soler A; García Marco JA; Deben G; Marín J; Tomás JF;
Leuk Lymphoma; 2022 Jan; 63(1):93-100. PubMed ID: 34459702
[TBL] [Abstract][Full Text] [Related]
8. Two rare cases of bronchus-associated lymphoid tissue lymphoma successfully treated with rituximab-bendamustine.
Panitz N; Gerhardt K; Becker C; Schleife H; Bach E; Opitz S; Schaudinn A; Platzbecker U; Kayser S
Clin Case Rep; 2021 Aug; 9(8):e04557. PubMed ID: 34401153
[TBL] [Abstract][Full Text] [Related]
9. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.
Yasuda H; Mori Y; Chiba A; Bai J; Murayama G; Matsushita Y; Miyake S; Komatsu N
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e810-e816. PubMed ID: 34393077
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.
Harb W; Lakhani NJ; Messmann R; Klencke B; Al-Katib AM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):823-830. PubMed ID: 34417162
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Biran N; Gourna Paleoudis E; Feinman R; Vesole DH; Zenreich J; Wang S; Ahn J; Bansal M; Rowley S; Donato M; Pecora AL; Richter J; Anand P; McBride L; Ivanovski K; Korngold R; Siegel DS
Am J Hematol; 2021 Nov; 96(11):E430-E433. PubMed ID: 34435374
[No Abstract] [Full Text] [Related]
14. Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Udagawa H; Sugiyama E; Harada T; Atagi S; Koyama R; Watanabe S; Nakamura Y; Harada D; Hataji O; Tanaka F; Kida H; Satouchi M; Maeno K; Inoue A; Yoh K; Yamane Y; Urata Y; Yoshioka H; Yamanaka T; Goto K
Transl Lung Cancer Res; 2021 Jul; 10(7):3059-3070. PubMed ID: 34430347
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Martin P; Bartlett NL; Chavez JC; Reagan JL; Smith SM; LaCasce AS; Jones J; Drew J; Wu C; Mulvey E; Revuelta MV; Cerchietti L; Leonard JP
Blood; 2022 Feb; 139(8):1147-1159. PubMed ID: 34428285
[TBL] [Abstract][Full Text] [Related]
16. Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.
Ohya K; Okuyama S; Ogata SY; Maeda K; Yamada K; Ohshima K; Tajima K
Ann Hematol; 2021 Nov; 100(11):2873-2875. PubMed ID: 34427738
[No Abstract] [Full Text] [Related]
17. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker S; Bittner A; Frick M; Kase J; Hoffmann J; Trenker C; Keller U; Bogner C; Hüttmann A; Dürig J; Janz M; Mathas S; Marks R; Krohn U; Na IK; Bullinger L; Schmitt CA
Leuk Lymphoma; 2022 Jan; 63(1):84-92. PubMed ID: 34414850
[TBL] [Abstract][Full Text] [Related]
19. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Staber PB; Jurczak W; Greil R; Vucinic V; Middeke JM; Montillo M; Munir T; Neumeister P; Schetelig J; Stilgenbauer S; Striebel F; Dirnberger-Hertweck M; Weirather J; Brugger W; Kelemen P; Wendtner CM; Woyach JA
Leuk Lymphoma; 2021 Dec; 62(14):3440-3451. PubMed ID: 34414843
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.
Suzuki K; Min CK; Kim K; Lee JJ; Shibayama H; Ko PS; Huang SY; Li SS; Ding B; Khurana M; Iida S
Int J Hematol; 2021 Dec; 114(6):653-663. PubMed ID: 34410635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
